References
Jimenez-Zepeda VH, Mikhael J, Winter A, Franke N, Masih-Khan E, Trudel S et al. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant 2012; 18: 773–779.
Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.
Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer, (e-pub ahead of print 15 November 2011; doi:10.1002/cncr.26662).
Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850.
Kroger N, Zeller W, Hassan HT, Kruger W, Renges H, Hummel K et al. Successful mobilization of peripheral blood stem cells in heavily pretreated myeloma patients with G-CSF alone. Ann Hematol 1998; 76: 257–262.
DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.
Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J et al. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011; 86: 488–495.
Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N et al. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-alpha therapy. Bone Marrow Transplant 1999; 24: 13–17.
Bakkus MH, Bouko Y, Samson D, Apperley JF, Thielemans K, Van Camp B et al. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. Br J Haematol 2004; 126: 665–674.
San Miguel JF, Almeida J, Mateo G, Blade J, Lopez-Berges C, Caballero D et al. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 2002; 99: 1853–1856.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Khaled, Y., Al-Hazzouri, A., Mizrachi, A. et al. Stem cell mobilization in heavily pretreated multiple myeloma patients with prior high dose melphalan and auto-SCT. Bone Marrow Transplant 48, 310–311 (2013). https://doi.org/10.1038/bmt.2012.135
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.135
- Springer Nature Limited